S-1090 is an orally-active cephalosporin under development by Shionogi, currently in phase III clinical trials [269191]. It has broad-spectrum activity (excluding Pseudomonas aeruginosa (P aeruginosa), Serratia marcescens (S marcescens) and Proteus vulgaris (P vulgaris)), a long half-life of about 3 h, and high serum protein binding of greater than 95% [221654], [166465]. Phase I pharmacokinetic trials of S-1090 in comparison to other oral cephalosporins, including cefdinir, showed the compound to have favorable characteristics. It had a higher plasma Cmax, longer half-life, and a larger AUC in healthy volunteers. Food intake increased the absorption and excretion of S-1090 after oral administration [187813].
Mazzaglia, G. (1999). S-1090 Shionogi. CURRENT OPINION IN ANTI-INFECTIVE INVESTIGATIONAL DRUGS, 1(1), 57-63.
S-1090 Shionogi
Mazzaglia G
1999
Abstract
S-1090 is an orally-active cephalosporin under development by Shionogi, currently in phase III clinical trials [269191]. It has broad-spectrum activity (excluding Pseudomonas aeruginosa (P aeruginosa), Serratia marcescens (S marcescens) and Proteus vulgaris (P vulgaris)), a long half-life of about 3 h, and high serum protein binding of greater than 95% [221654], [166465]. Phase I pharmacokinetic trials of S-1090 in comparison to other oral cephalosporins, including cefdinir, showed the compound to have favorable characteristics. It had a higher plasma Cmax, longer half-life, and a larger AUC in healthy volunteers. Food intake increased the absorption and excretion of S-1090 after oral administration [187813].
| File | Dimensione | Formato | |
|---|---|---|---|
|
1999 Curr Opinion.pdf
Solo gestori archivio
Dimensione
103.28 kB
Formato
Adobe PDF
|
103.28 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
